CompuGroup Medical US announces CEO transition
|
EQS-News: CompuGroup Medical SE & Co. KGaA
/ Key word(s): Personnel
CompuGroup Medical US announces CEO transition
Austin, TX – Underlining the commitment to its second largest market worldwide by revenue, CompuGroup Medical announces the appointment of Benedikt Brueckle as its new Chief Executive Officer for the US, effective January 1, 2025. Benedikt Brueckle is a respected and experienced leader in the healthcare IT industry and will succeed Derek Pickell, who is set to retire at the end of 2024 after a distinguished tenure. In the past three years, CompuGroup Medical US has achieved excellent profitable growth, partly as a result of the launch of converting its APRIMA customers to CGM’s inhouse Clearinghouse eMEDIX. CGM US has successfully grown its number of customers over the recent years. With its broadened reach in the physician office space CGM US is excellently positioned to drive the digitization of the patient journey. Product quality and customer satisfaction are reflected in several awards, including the 2024 Best in KLAS Awards for ARIA Health Services and TOP 3 for APRIMA. "We are very grateful for Derek Pickell's leadership and contributions to CompuGroup Medical US", said Michael Rauch, CEO of CompuGroup Medical SE & Co. KGaA. "As we welcome Benedikt Brueckle as our new US CEO, we are confident that his leadership will continue to propel the company forward, driving innovation and excellence in healthcare IT." Derek Pickell, the outgoing US CEO, has led CompuGroup Medical US with distinction, overseeing steady growth and expansion. Under his leadership, the company has achieved numerous milestones such as the successful integration of eMDs. "I am grateful for the opportunity to work with this amazing leadership team across CompuGroup Medical and am excited to spend the remainder of the year helping Benedikt have a very successful transition into the CEO role and ensuring clients, resellers, business partners, and our employees are excited about the transition", said Derek Pickell. Benedikt Brueckle has been with CompuGroup Medical for more than 13 years and led the acquisition of eMDs in 2020. He brings a wealth of experience and a proven track record of success in healthcare technology, thereby uniquely positioned to lead CompuGroup Medical US into its next chapter. His expertise in driving innovation and fostering strategic partnerships will be critical as the company navigates the evolving healthcare landscape. "With its Ambulatory and Laboratory Information Systems, CompuGroup Medical US has a unique selling proposition that is unseen in the US ambulatory market and will benefit everyone from the smaller practices up to larger health systems", said Benedikt Brueckle. "It underlines CGM’s excellent position in the US market, by being the only vendor of ambulatory Electronic Health Records and Practice Management Systems, that not only has its own Medical Clearinghouse, eMEDIX, but also can cover the complete Patient Lifecycle by having its own LIS. CGM US is well positioned to continue delivering profitably growth going forward."
25.03.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. |
| Language: | English |
| Company: | CompuGroup Medical SE & Co. KGaA |
| Maria Trost 21 | |
| 56070 Koblenz | |
| Germany | |
| Phone: | +49 (0)160 3630362 |
| Fax: | +49 (0)261 8000 3200 |
| E-mail: | investor@cgm.com |
| Internet: | www.cgm.com |
| ISIN: | DE000A288904 |
| WKN: | A28890 |
| Indices: | SDAX, TecDAX |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 1866503 |
| End of News | EQS News Service |
|
|
1866503 25.03.2024 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.